Our clinical cancer tests will use FISH technology already available
in the lab. CLG will offer the Abbott/Vysis™ PathVysion™ HER-2/neu test
to stratify breast cancer patients, LAVysion™ EGFR test to stratify lung
cancer patients for therapy and Urovysion™ Bladder Cancer test for
bladder cancer detection, as well as other tests.
|
| Breast cancer (paraffin embedded tissue sections or FNA) |
- HER-2/neu gene amplification
- TOPO-2A gene amplification
|
| Uroepithelial (bladder) cancer detection panel (urine or bladder washings) |
- Chromosome 3, 7, 9p21,17 copy number detection
|
| Oligodendrioglioma (paraffin embedded tissue sections) |
- 1p/19q deletion status
- EGFR gene amplification detection
|
| Non-small cell lung cancer Panel |
- EGFR, C-MYC, 6CEP, 5p15.2 copy number detection
|
| Synovial Sarcoma diagnosis from paraffin embedded tissue sections |
|
| Ewings Sarcoma diagnosis from paraffin embedded tissue sections |
|
